Grifols heads into its fourth session in the red after Barclays’ warning on the exchange rate
Grifols shares lead the falls on the Ibex with a correction of 2.35% to 11.19 euros per share at the close of this article and They thus extend a depreciation that is already close to 7% in the last five sessions. Although the cut is not due to any significant movement that occurred this Wednesday, red numbers have become a common trend in the company’s stock trading after the analysis firm Barclay fueled sales by indicating that the exchange rate represents a risk for Grifols’ sales forecasts in 2025, despite pointing out that free cash flow will probably remain positive.
This report, in the run-up to the third quarter results that the Catalan multinational will present next November 4, is playing a key role in the sessions prior to the market appointment. “The exchange rate represents a risk for Grifols’ sales forecasts for fiscal year 2025, since free cash flow remains isolated,” revealed the document sent last Monday by Barclays, where sales for the third quarter of 2025 of 1,853 million euros are seen, driven mainly by Biopharma (-2%) and Diagnostics (0%).
For the adjusted gross operating profit (Ebitda), Barclays, which reiterated its target price of 15 euros per share, estimated 474 million euros. It should be remembered that the group of blood products closed the first half of the year with a net profit of 177 million euros388% more than the 36 a year ago. In this period, the company obtained revenues of 3,677 million, 7% more at constant exchange rates, and adjusted Ebitda reached 876 million, 12.7% more, with a margin of 23.8%.
News in expansion…
